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FRI0194 USE OF GLORESPONSETM NF-κB-RE-LUC2P HEK293 CELLS TO MONITOR DRUG AND ANTI-DRUG ANTIBODY LEVELS IN SERUM
Background: Rheumatoid Arthritis (RA) is often treated with anti-TNFα such as infliximab (Ifx) which in a long-term treatment can lead to the development of anti-Ifx antibodies (ATI), resulting in an interference with the drug activity. The investigation of the bioactivity of the circulating drug and antibodies present in patients sera with inflammatory diseases will allow to harmonize the different published data using both bioassays as well as immunoassays. Objectives: To evaluate the ability of the Promega bioassay in the quantification of both Ifx and ATI in serum from RA patients. To compare the bioassay performance between capture-and bridging-ELISA. Methods: Serum Ifx-trough levels were determined in 50 samples from patients with RA. To measure Ifx, the bioassay uses GloResponse™ NF-κB-RE-luc2P HEK293 cell line, which responses to TNFα resulting in modulation of NF-κB activity (Promega Corp., Madison, USA). This is an ease on performing reporter assay (add-mix-read) that detects the serum Ifx by inhibition of the luminiscent signal due to TNFα. The inhibition of the Ifx-driven luminescent signal is reverted by the presence of ATI in the serum. ATI concentration is determined using a standard curve obtained with a serial dilution of a serum sample known to have ATI. A relative luminescent unit (RLU) is arbitrarily defined. The immunoassay for Ifx (ELISA) captures recombinant TNFα, via a monoclonal antibody that does not interfere with the serum Ifx binding to TNFα. The reaction is developed with a biotinylated anti-idiotype antibody 1 (Cut-off for Ifx: 0.050 μg/ml). The ELISA to detect ATI takes advantage of the bivalency of most IgG subclasses, allowing the antibodies present in serum to bridge between Ifx-coated onto the plate with biotinylated Ifx in fluid phase 1 (Cut-off for ATI 50 AU/ml). Results: Addition of TNFα on GloResponse cells induces the production of luciferase resulting in an increase of the luminescent signal in a dose-response. Addition of Ifx on GloResponse cells +TNFα decreases the production of luciferase and therefore the luminescent signal falls (r 2 =0.99). Addition of anti-Ifx (in relative units) on GloResponse cells +TNFα + Ifx restore the production of luciferase resulting in an increase of the luminescent signal (r 2 =0.98). Serum Ifx concentrations were sorted into 3 groups (low, medium and high following ELISA levels). Similar number of positive Ifx results was found (30 samples, 55% by ELISA vs 28 samples, 52% by bioassay; κ=0.92; p=0.56) along with a significant Pearson correlation (r=0.8) between methods. The bioassay to measure ATI activity showed lower sensitivity than ELISA (9/31, 29% by ELISA vs 4/31, 13% by bioassay, κ=0.53, p=0.22) with a slightly less correlation for ATI levels by both methods (r=0.26). Conclusions: Bioassay using GloResponse NF-κB cell line can be performed to monitor therapeutic drug of TNFα blocker and are useful to detect the presence of anti-drug antibody in serum samples treated with anti-TNFα antibodies.
Comparison with ELISA method shows in most of the case the same data. ® Quick Anti-IFX, Progenika, Spain) to detect ATI in routine clinical practice in rheumatic and gastroenterology patients treated with the reference IFX or the biosimilar CT-P13 attending the infusion center with the ELISA technique as a reference. The POC test is a qualitative immunochromatographic assay based on lateral flow technology to detect ATI (including biosimilar CT-P13) in either fingerprick or serum or venous whole blood. Consecutive patients (initiating or under maintenance therapy) were recruited and tested in La Paz and Basurto University hospitals with the rapid test in capillary and venous whole blood specimens immediately before the infusion. ATI test results were read visually with the POC test in 30 min, just before the patient started the infusion. Trough sera were also collected for subsequent analysis with the rapid test and benchmarked with Promonitor ® -Anti-IFX ELISA (Progenika, Spain). Follow-up time was 6 months. ELISA quantitative results were categorized as positive and negative to allow comparisons with the qualitative rapid test. Results: Ninety consecutive patients were recruited (a total of 137 visits in the 6 months follow-up) accounting for a total of 137 sera, 137 fingerpricks and 71 venous whole blood samples. Overall, 8 (8.9%) 
